We see how Mr Gill contributes to TLX
Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turnaround strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.
and
Change of Company Secretary The Company also advises that Genevieve Ryan has tendered her resignation as Company Secretary, effective today, April 2, 2026.
david-gill-as-nonexecutive-director
https://telixpharma.com/team-member/christian-behrenbruch/
Todays Board>
https://-and-2025-annual-report.
Receipts from customers has grown .. But the Payments to suppliers and customer is in lock step at (710,551M)
Precision Medicine is a Revenue giver..
Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging
What, and How long this will take 1month 2 month!
Dr. David N. Cade, Telix Group Chief Medical Officer, said, “We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.” Maggie Haynes, Executive Director, Head for the Cure Foundation, added: “Our community is encouraged by the FDA’s ongoing engagement and guidance to the sponsor and support for the Expanded Access Program for TLX101-Px. We are hopeful of an expedited review, so this important and proven imaging option can become available to those who urgently need it.”
Chart looks ok .. a break out here to get on
Financial performance and strategy Let me now turn to financial performance and strategy. Telix delivered strong financial performance in 2024. I note that we moved to U.S. dollar reporting on 1 January this year and quote the following figures in that currency. Telix generated total revenue of $517 million, an increase of 55% from $334 million in 2023. In Q1 2025, we announced a positive quarterly revenue of $186 million, a 62% increase year-over-year, from $115 million in Q1 2024. In terms of total shareholder return, or TSR, strong growth in our share price has contributed to an impressive return of 76% over the past twelve months11.
https://hotcopper.com.au/threads/ann-telix-annual-general-meeting-chairman-and-ceo-addresses.8591763/
https://hotcopper.com.au/threads/ann-telix-annual-general-meeting-presentation.8591760/
Governance and sustainability Let me now turn to governance and sustainability. It is important to observe that long-term growth must also be sustainable, and Telix’s 2024 Sustainability report demonstrates the ongoing work of the Company across what we call the Five P’s: Purpose, People, Planet, Principles and Performance. I recommend this report to you if you wish to know more about our work in these areas. From 2026, we will be required to report under Australia’s mandatory climate reporting regime and the Company has undertaken a significant amount of work to ensure we have the data we need to comply with this important new initiative.
Today price reaction:
Last
$25.62
Change
0.270(1.07%)
Mkt cap !
$8.571B
